Compare NNBR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | ENTX |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 147.4M |
| IPO Year | 1996 | 2015 |
| Metric | NNBR | ENTX |
|---|---|---|
| Price | $3.36 | $2.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 2.8M | 335.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.60 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $770,657,000.00 | $42,000.00 |
| Revenue This Year | $8.60 | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | ★ N/A | $13.27 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $0.91 |
| 52 Week High | $4.48 | $4.20 |
| Indicator | NNBR | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 50.66 |
| Support Level | $2.99 | $2.66 |
| Resistance Level | $4.39 | $3.10 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 11.47 | 13.17 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with materials science expertise to design and manufacture high-precision components and solutions. The company operates through two segments: Mobile Solutions, which generates maximum revenue and focuses on the automotive, general industrial, and medical end markets, manufacturing tight-tolerance components used in battery electric, hybrid electric, and internal combustion engine vehicles, braking, transmissions, fuel systems, HVAC, and diesel systems; and Power Solutions, which focuses on the electrical, general industrial, automotive, medical, and aerospace and defense end markets and manufactures high-precision metal components, assemblies, contact assemblies, and precision stampings.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.